Form 4: Lifecore Biomedical Director Acquires Shares

Director Paul Harold Johnson acquired 24,554 shares of Lifecore Biomedical, Inc. common stock on August 19, 2024.

Summary

• On August 19, 2024, Paul Harold Johnson, a director of Lifecore Biomedical, Inc., acquired 24,554 shares of common stock.
• The shares were acquired directly.
• These shares were acquired in the form of restricted stock units that convert into common stock on a 1 for 1 basis.
• The restricted stock units vest on the earlier of July 8, 2025, or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock acquisition, which can be seen as a positive sign but doesn't provide enough information to strongly influence sentiment.

Positives

• A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units is contingent on future dates and the annual meeting of stockholders.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.

Key Dates